A novel SCN1A mutation identified in a Chinese family with familial hemiplegic migraine: A case report

Abstract

Background

Familial hemiplegic migraine (FHM) is a rare type of migraine with aura that is characterized by transient hemiparesis. Mutations in three genes (CACNA1A, ATP1A2, and SCN1A) have been found to cause FHM. Among these, nine SCN1A gene mutations were reported to cause familial hemiplegic migraine type 3 (FHM3). However, none of them was reported in China.

Method

The clinical manifestations of a Chinese FHM family were recorded and all coding exons and flanking intronic regions of the CACNA1A, ATP1A2, and SCN1A genes were tested for mutations.

Results

All FHM patients in the investigated family have typical hemiplegic migraine attacks characteristic of FHM. We identified a novel mutation (p.Leu1670Trp) of the SCN1A gene. The affected amino acid is highly conserved across different species and therefore likely plays an important role in SCN1A gene function.

Conclusion

The identification of a novel mutation in the SCN1A gene in the Chinese population may further aid in the understanding of FHM genetics.

Keywords

Migraine familial hemiplegic migraine SCN1A gene China

Introduction

Familial hemiplegic migraine (FHM) is a rare type of migraine with aura, characterized by transient attacks with motor aura (1). FHM follows autosomal dominant inheritance patterns. So far, mutations in three genes, CACNA1A, ATP1A2, and SCN1A have been found to be responsible for familial hemiplegic migraine type 1 (FHM1), familial hemiplegic migraine type 2 (FHM2), and familial hemiplegic migraine type 3 (FHM3), respectively (2 –4).

More than 20 different missense mutations of CACNA1A (FHM1) (5) and over 30 different missense mutation of ATP1A2 (FHM2) have been identified as causing FHM (6). However, only nine missense mutations of the SCN1A gene have been reported to cause FHM3 (2,5,7 –11), and none of them have been reported in China. The aim of this study was to further investigate the genetics of FHM in the Chinese population. Here we report a Chinese FHM3 family with a novel mutation in the SCN1A gene.

Subjects and methods

Patients

The proband (patient III-20), a 27-year-old Chinese male, had recurrent headache attacks from 16 to 27 years of age. These attacks were of moderate intensity, and usually originated in the bilateral temple. Routine physical activity aggravated headaches. The total number of headache attacks was five. Two out of the five attacks were accompanied by nausea and/or vomiting. The first attack happened at the age of 16, the second episode at the age of 21, and three more episodes occurred at 27 years of age. These headache attacks were preceded by aura symptoms, including visual disturbances, speech problems, sensory disturbances, and motor weakness. In general, the aura symptoms lasted 2–3 hours and then the patient gradually recovered. The visual disturbances always lasted at least 20 min and were described as increased scotomata and filled squares in the bilateral visual field. The speech problems were described as the inability to form a coherent sentence while being able to fully comprehend sentences. Sensory problems were unilateral or bilateral and were described as a spreading numbness of the left or right limbs, whereas motor weakness always located unilaterally and was described as movements out of control. For instance, the hand could not hold items steadily and there was a drag to the gait while walking. The patient presented with prolonged symptoms for 30–40 hours during the last episode. Neurological examinations were unremarkable. Cerebral magnetic resonance imaging (MRI) and Magnetic Resonance Angiography (MRA) showed no abnormalities.

A neurologist interviewed all family members. The proband's mother (patient II-9) had suffered from typical migraine attacks (bilateral moderate pulsatile headache aggravated by walking, accompanied by nausea and vomiting) for 37 years, and with five attacks per year on average. The aura symptoms were similar to the proband’s symptoms, including bilateral visual symptoms (scotomata), speech difficulties (aphasia), and one-side sensory and motor disturbance. The patient also suffers from depressive disorder and hypotension.

The proband’s deceased grandfather’s history was obtained from memory by the proband (Table 1).

Table 1.

Clinical features of FHM patients in this family. NK: not known; NA: not applicable.

			Aura				Headache characteristics
	Age (years)	Attack frequency	Visual	Sensory	Motor	Speech	Duration	Side	Character	Nausea/vomiting/ photophobia/ phonophobia	Intensity	Other medical history	Genotype
I-1	Deceased	NK	NK	NK	Yes	Yes	NK	NK	NK	+/+/−/−	NK	NK	NK
III-20(proban)	27	4/11years	Yes	Yes	Yes	Yes	Up to 40 hours	Bilateral	NA	+/+/−/−	Moderate	No	p.Leu1670Trp/WT
III-17	38	NA	Yes	NA	Yes	yes	Up to 24 hours	Bilateral	Pulsatile	+/+/−/−	Moderate	No	p.Leu1670Trp/WT
II-5	59	2/year	Yes	NA	Yes	NA	2–4 hours	Bilateral	Pulsatile	+/+/−/−	Moderate	No	p.Leu1670Trp/WT
II-9	49	4–5/year	Yes	Yes	Yes	Yes	Up to 24 hours	Bilateral	Pulsatile	+/+/−/−	Moderate	Depressive disorder; Hypotension	p.Leu1670Trp/WT
II-11	46	5–6/year	Yes	Yes	Yes	Yes	Up to 24 hours	Bilateral	Pulsatile	+/+/−/−	Moderate	No	p.Leu1670Trp/WT

Patient II-5 (Figure 1, Table 1), a 59-year-old maternal uncle, had headache attacks with nausea, vomiting, visual symptoms (black spots), and weakness in one arm and leg. These attacks lasted 2–4 hours.

Figure 1.

Family tree of a Chinese FHM family. Males and females are represented by squares and circles, respectively. The arrow indicates the proband. The diagonal line indicates a deceased family member. Filled black symbols represent FHM patients. “+” represents a carrier of the SCA1N mutation (p.Leu1670Trp); “−” represents family members without the SCN1A mutation.

Patient II-11, a 46-year-old maternal uncle (Figure 1, Table 1) had suffered from migraine with nausea and vomiting since youth. Aura symptoms included visual (black spots), speech (aphasia), and sensory, with motor weakness in one arm and leg.

Patient III-17, a 38-year-old maternal cousin (Figure 1, Table 1), had migraine attacks with visual symptoms, speech difficulties, and motor weakness in one arm.

None of the family members reported childhood epilepsy or other SCN1A associated syndromes, such as cerebellar ataxia and elicited repetitive daily blindness.

Genetic analysis

Genomic DNA from family members was extracted from peripheral blood leukocytes according to standard procedures (12). The FHM genes CACNA1A, ATP1A2, and SCN1A were analyzed by direct sequencing of polymerase chain reaction. Causal mutations in the CACNA1A and ATP1A2 gene were excluded by testing all coding exons and flanking intronic regions. All 26 exons and flanking intronic sequences of the SCN1A gene were analyzed.

Results

A novel heterozygous point mutation in exon 26 (c.5009T > G, p.Leu1670Trp) of the SCN1A gene was identified by mutation scanning of the proband and his family. The mutation was found in the proband’s genome and all his relatives who were affected with FHM. It was absent in other unaffected family members (Figure 1). This mutation has not been described in the literature and is not reported in the Single Nucleotide Polymorphism Database (http://www.ncbi.nlm.nih.gov/snp).

The SCN1A gene encodes for the α₁ subunit of the Na_V1.1 sodium channel, containing four homologous domains (DI-DIV). Each domain consists of six transmembrane segments. Leucine¹⁶⁷⁰ is located at the intracellular loop between the S4 and S5 segment in domain IV. The missense mutation leads to the replacement of leucine by tryptophan. Although no missense mutations were reported at this location, various known mutations near leucine¹⁶⁷⁰, for example missense mutation p.Pro1668Ala and p.Met1664Lys, have been identified as causing SMEI (severe myoclonic epilepsy of infancy, also known as Dravet's syndrome) or GEFS+ (generalized epilepsy with febrile seizure plus) (13,14).

Moreover, leucine¹⁶⁷⁰ is highly conserved between different species (Figure 2). Different bioinformatics prediction programs, such as SIFT (Deleterious (−5.216)) and PolyPhen2 (probably damaging (1.0)) indicate that the Leucine¹⁶⁷⁰ mutation is likely pathogenic.

Figure 2.

Protein alignment of different SCN1A sequences from several species. Arrow indicates the location of the p.Leu1670Trp mutation with highly conserved leucine¹⁶⁷⁰.

Discussion

Here we report a novel missense mutation, p.Leu1670Trp, in a FHM3 family in China. The FHM3 patients in this family display very similar migraine attack symptoms. The attack frequency varies from four episodes during an 11-year period to 5–6 episodes per year. Seizures or other SCN1A-associated syndromes were not observed. To our knowledge this is the first SCN1A gene mutation reported in China and the mutation itself has not previously been reported in the literature. Although no functional tests were performed for this novel mutation, several lines of evidence indicate that the mutation likely has an impact on gene function. The mutation co-segregated with FHM in this family. Similar nearby missense mutations present with epileptic phenotypes. Leucine¹⁶⁷⁰ is a highly conserved amino acid in sodium channel α1 subunits across different species (Figure 2), and two bioinformatics prediction programs both indicate that the mutation is most likely pathogenic.

Previous studies have reported three FHM patients in China. Regretfully, only our study performed mutational analysis of the patient’s and the family members’ genes. Review of the clinical data of the previous three FHM cases in China revealed that their clinical manifestations did not involve seizures or other syndromes (15 –17). However, only limited information is available for these FHM cases.

The p.Leu1670Trp mutation is the sixth mutation found to cause pure FHM3. The other five mutations are Q1489K, L1649Q, L1624P, I1498M, and F1661L (2,7,10,11), while other SCN1A mutations are associated with epileptic seizures or other symptoms. Our study indicates that screening for the SCN1A gene mutation should be considered in FHM when no mutation is found in the CACNA1A and ATP1A2 gene (7).

In conclusion, we identified a novel SCN1A gene mutation in a Chinese FHM3 family. Our case report can contribute to a better understanding of the genetic underpinnings of FHM, in particular in China.

Clinical implications

A new mutation point (p.Leu1670Trp) for of FHM3 was identified that can be used for gene testing and consultation of FHM patients.

This the first report of a SCN1A gene mutation in a Chinese FHM family.

Our new finding may focus more attention on FHM and genetic research in China.

Footnotes

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References

Bes

Kunkel

Lance

et al.

The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629–808.

Dichgans

Freilinger

Eckstein

et al.

Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005; 366: 371–377.

Ophoff

Terwindt

Vergouwe

et al.

Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87: 543–552.

Pietrobon

. Familial hemiplegic migraine. Neurotherapeutics 2007; 4: 274–284.

de Vries

Frants

Ferrari

et al.

Molecular genetics of migraine. Hum Genet 2009; 126: 115–132.

Jurkat-Rott

Freilinger

Dreier

et al.

Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants. Neurology 2004; 62: 1857–1861.

Weller

Pelzer

de Vries

et al.

Two novel SCN1A mutations identified in families with familial hemiplegic migraine. Cephalalgia 2014; 34: 1062–1069.

Gargus

Tournay

. Novel mutation confirms seizure locus SCN1A is also familial hemiplegic migraine locus FHM3. Pediatr Neurol 2007; 37: 407–410.

Vahedi

Depienne

Le Fort

et al.

Elicited repetitive daily blindness: A new phenotype associated with hemiplegic migraine and SCN1A mutations. Neurology 2009; 72: 1178–1183.

10.

Vanmolkot KR, Babini E, de Vries B, et al. The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with familial hemiplegic migraine: Genetic and functional studies. Mutation in brief #957. Hum Mutat 2007; 28: 522.

11.

Fan C, Wolking S, Lehmann-Horn F, et al. Early-onset familial hemiplegic migraine due to a novel SCN1A mutation. Cephalalgia 2016; 36: 1238–1247.

12.

Miller

Dykes

Polesky

. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215–1215.

13.

Nabbout

Gennaro

Dalla Bernardina

et al.

Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology 2003; 60: 1961–1967.

14.

Depienne

Trouillard

Saint-Martin

et al.

Spectrum of SCN1A gene mutations associated with Dravet syndrome: Analysis of 333 patients. J Med Genet 2009; 46: 183–191.

15.

Jianguo

. A pedigree with familial hemiplegic migraine. J Clin Inter Med 2009; 26: 68–69.

16.

Sun

. A report of a family with familial hemiplegic migraine. Med & Pharm J Chin PLA 2010; 22: 559–559.

17.

Side J, Mingshan T, Yaobin Z, et al. A case of familial hemiplegic migraine. Chin J Clinicians (Electronic Edition) 2011; 5: 5539.